thebench.bio #1 Ecosystem for the Bio-Tech Industry
All Flow Cytometry questions

Question 19 of 20 Advanced Practical

How would you validate a flow cytometry assay for clinical trial samples?

Short answer

Use a fit-for-purpose validation: define the intended use first, then test the parameters that use depends on, such as precision, specimen stability, sensitivity and robustness. Cell-based assays rarely have true reference standards, so the plan leans on real specimens, predefined acceptance criteria and stability across shipping and storage.

Why

A flow assay measuring receptor occupancy as an exploratory endpoint needs less validation than one used to select patients. Selliah and colleagues describe four levels, from limited validation for research to transfer validation between sites. All of them choose parameters by intended use, consistent with CLSI H62 and the industry white papers.

The ICSH and ICCS guidance asks that the sample type, anticoagulant, processing steps and stability be validated and specified. Unlike a small-molecule assay, there is usually no reference material with known cell counts. Accuracy is often replaced by comparison with an established method, and precision and stability carry most of the weight.

Stability is decisive in trials, because samples travel from clinics to a central lab. The validation report becomes the basis for interpreting trial data, so criteria have to be written before experiments start.

How to work it through

  1. Write the intended use, the readouts reported and the decisions they support.
  2. Choose validation parameters for that use, typically intra-assay and inter-assay precision, specimen stability, sensitivity at the low end and robustness.
  3. Set acceptance criteria in a plan before testing.
  4. Test precision with real specimens spanning low, medium and high values, across days, operators and instruments.
  5. Test stability by holding specimens for the planned shipping and storage times and conditions.
  6. Lock the gating template and document reagent lots, then report deviations and the final validated conditions.

An example

A trial needs the frequency of activated CD8 T cells in blood, shipped to a central lab within 48 hours. Five donors are tested in triplicate on three days by two operators. The inter-assay coefficient of variation is 9 percent at a frequency of 12 percent but 28 percent at 0.8 percent.

Stability holds at 24 hours but the readout falls 35 percent at 48 hours. The lab narrows the shipping window to 24 hours and sets a reportable lower limit of 1 percent.

Where the answer stops holding

The level of validation must rise when results become a primary endpoint or support a regulatory claim, and requirements can differ by region and laboratory accreditation. Donors in validation may not reflect the disease, where antigen levels and viability differ. A validated assay still needs ongoing quality control, because reagent lots and instruments change during a long trial.

A strong answer covers

  • Intended use drives which parameters are validated
  • Precision with real specimens across days and operators
  • Specimen stability for real shipping conditions
  • Predefined acceptance criteria
  • Lack of reference materials changes how accuracy is shown

Common mistakes

  • Copying a small-molecule bioanalytical validation template unchanged
  • Testing precision only on healthy donors with high-frequency populations
  • Validating stability at the lab bench instead of under shipping conditions